{"Symbol": "INFI", "AssetType": "Common Stock", "Name": "Infinity Pharmaceuticals, Inc", "Description": "Infinity Pharmaceuticals, Inc., a biopharmaceutical company, focuses on developing novel medicines for people with cancer. It offers IPI-549, an orally administered, clinical-stage, immuno-oncology product candidate that selectively inhibits the enzyme phosphoinositide-3-kinase-gamma Its product candidate is IPI-549, an orally administered clinical-stage immuno-oncology product candidate that inhibits the enzyme phosphoinositide-3-kinase-gamma (PI3K-gamma), which is in Phase 1/1b clinical study. The company has strategic alliances with Intellikine, Inc. to discover, develop, and commercialize pharmaceutical products targeting the delta and/or gamma isoforms of PI3K; Verastem, Inc. to research, develop, commercialize, and manufacture duvelisib and products containing duvelisib, as well as duvelisib program for patients with relapsed or refractory chronic lymphocytic leukemia or small lymphocytic lymphoma; and PellePharm, Inc. to develop and commercialize rights to its hedgehog inhibitor program, IPI-926, a clinical-stage product candidate, as well as collaboration agreements with Arcus Biosciences, Inc., F. Hoffmann-La Roche Ltd., and Bristol-Myers Squibb Company. Infinity Pharmaceuticals, Inc. is headquartered in Cambridge, Massachusetts.", "Exchange": "NASDAQ", "Currency": "USD", "Country": "USA", "Sector": "Healthcare", "Industry": "Biotechnology", "Address": "1100 Massachusetts Avenue, Cambridge, MA, United States, 02138", "FullTimeEmployees": "25", "FiscalYearEnd": "December", "LatestQuarter": "2020-06-30", "MarketCapitalization": "66523892", "EBITDA": "-18712000", "PERatio": "None", "PEGRatio": "-0.05", "BookValue": "0.326", "DividendPerShare": "None", "DividendYield": "0", "EPS": "-0.336", "RevenuePerShareTTM": "0.025", "ProfitMargin": "0", "OperatingMarginTTM": "-28.8971", "ReturnOnAssetsTTM": "-0.4436", "ReturnOnEquityTTM": "-4.7468", "RevenueTTM": "1438000", "GrossProfitTTM": "-31375000", "DilutedEPSTTM": "-0.754", "QuarterlyEarningsGrowthYOY": "0", "QuarterlyRevenueGrowthYOY": "0.401", "AnalystTargetPrice": "2.5", "TrailingPE": "0", "ForwardPE": "0", "PriceToSalesRatioTTM": "45.3569", "PriceToBookRatio": "8.0285", "EVToRevenue": "52.9232", "EVToEBITDA": "0", "Beta": "1.7549", "52WeekHigh": "1.68", "52WeekLow": "0.6", "50DayMovingAverage": "1.0131", "200DayMovingAverage": "0.9945", "SharesOutstanding": "58870700", "SharesFloat": "39346788", "SharesShort": "46726", "SharesShortPriorMonth": "48587", "ShortRatio": "0.21", "ShortPercentOutstanding": "0", "ShortPercentFloat": "0.0038", "PercentInsiders": "3.514", "PercentInstitutions": "50.639", "ForwardAnnualDividendRate": "0", "ForwardAnnualDividendYield": "0", "PayoutRatio": "0", "DividendDate": "None", "ExDividendDate": "None", "LastSplitFactor": "1:4", "LastSplitDate": "2006-09-13"}